Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $58 to $49.
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $58 to $49.